Ariel Dora Stern
Ariel Dora Stern
Associate Professor, Harvard Business School
Dirección de correo verificada de - Página principal
Citado por
Citado por
Physician beliefs and patient preferences: a new look at regional variation in health care spending
D Cutler, JS Skinner, AD Stern, D Wennberg
American Economic Journal: Economic Policy 11 (1), 192-221, 2019
Will the stork return to Europe and Japan? Understanding fertility within developed nations
J Feyrer, B Sacerdote, AD Stern
Journal of Economic Perspectives 22 (3), 3-22, 2008
Did the rust belt become shiny? A study of cities and counties that lost steel and auto jobs in the 1980s [with Comments]
J Feyrer, B Sacerdote, AD Stern, A Saiz, WC Strange
Brookings-Wharton Papers on Urban Affairs, 41-102, 2007
Evaluating the impact of the Baby-Friendly Hospital Initiative on breast-feeding rates: a multi-state analysis
SS Hawkins, AD Stern, CF Baum, MW Gillman
Public health nutrition 18 (2), 189-197, 2015
Compliance with the Baby-Friendly Hospital Initiative and impact on breastfeeding rates
SS Hawkins, AD Stern, CF Baum, MW Gillman
Archives of Disease in Childhood-Fetal and Neonatal Edition 99 (2), F138-F143, 2014
Innovation under regulatory uncertainty: Evidence from medical technology
AD Stern
Journal of public economics 145, 181-200, 2017
Do state breastfeeding laws in the USA promote breast feeding?
SS Hawkins, AD Stern, MW Gillman
J Epidemiol Community Health 67 (3), 250-256, 2013
Limits on use of health economic assessments for rare diseases
HI Hyry, AD Stern, TM Cox, JCP Roos
QJM: An International Journal of Medicine 107 (3), 241-245, 2014
Adaptive platform trials: definition, design, conduct and reporting considerations.
DC Angus, BM Alexander, S Berry, M Buxton, R Lewis, M Paoloni, ...
Nature Reviews Drug Discovery 18 (10), 797-808, 2019
The impact of the entry of biosimilars: evidence from Europe
FMS Morton, AD Stern, S Stern
Review of Industrial Organization 53 (1), 173-210, 2018
How economics can shape precision medicines
AD Stern, BM Alexander, A Chandra
Science 355 (6330), 1131-1133, 2017
Innovation incentives and biomarkers
AD Stern, BM Alexander, A Chandra
Clinical Pharmacology & Therapeutics 103 (1), 34-36, 2018
Characterizing the drug development pipeline for precision medicines
A Chandra, C Garthwaite, AD Stern
National Bureau of Economic Research Working Paper Series, 2017
Economic implications of the Society for Assisted Reproductive Technology embryo transfer guidelines: healthcare dollars saved by reducing iatrogenic triplets
MS Lee, BT Evans, AD Stern, MD Hornstein
Fertility and sterility 106 (1), 189-195. e3, 2016
It’s time to reform the Orphan Drug Act
N Bagley, A Chandra, C Garthwaite, AD Stern
NEJM Catalyst 4 (6), 2018
Challenges and opportunities in software-driven medical devices
WJ Gordon, AD Stern
Nature biomedical engineering 3 (7), 493-497, 2019
The impact of price regulation on the availability of new drugs in Germany
AD Stern, F Pietrulla, A Herr, AS Kesselheim, A Sarpatwari
Health Affairs 38 (7), 1182-1187, 2019
Cybersecurity features of digital medical devices: an analysis of FDA product summaries
AD Stern, WJ Gordon, AB Landman, DB Kramer
BMJ open 9 (6), e025374, 2019
The Orphan Drug Act at 35: observations and an outlook for the twenty-first century
N Bagley, B Berger, A Chandra, C Garthwaite, AD Stern
Innovation Policy and the Economy 19 (1), 97-137, 2019
Recalls, innovation, and competitor response: Evidence from medical device firms
G Ball, JT Macher, AD Stern
Harvard Business School Working Paper 19-028, 2018
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20